Search
Climb Bio Inc
CLYMAdd to Watchlist
12.900USD
-0.390-2.93%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
616.21MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.93%
5 Days
-1.38%
1 Month
+18.24%
6 Months
+244.00%
Year to Date
+222.50%
1 Year
+907.81%
Key Figures
13.095Open
13.490High
1.18MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.46%Turnover Ratio
13.290Prev. Close
12.430Low
10.96MTurnover
LossP/E Static
4.16P/B
0.00%Div Yield TTM
-29.90%ROA
12.48052wk High
0.82Volume Ratio
-73.90MNet Profit
47.77MShares
-0.7757EPS TTM
0.10Beta
-30.92%ROE
1.16052wk Low
7.98%Amplitude
--Gross Margin
616.21MMarket Cap
3.64Reward/Risk
6.00%Risk Rate
TradingKey Stock Score
No stock score available due to insufficient data.
Climb Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Climb Bio Inc Info
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Ticker SymbolCLYM
CompanyClimb Bio Inc
CEOBrennan (Aoife M)
Websitehttps://climbbio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Climb Bio Inc (CLYM)?
The current price of Climb Bio Inc (CLYM) is 12.90.
What is the symbol of Climb Bio Inc?
The ticker symbol of Climb Bio Inc is CLYM.
What is the 52-week high of Climb Bio Inc?
The 52-week high of Climb Bio Inc is 12.48.
What is the 52-week low of Climb Bio Inc?
The 52-week low of Climb Bio Inc is 1.16.
What is the market capitalization of Climb Bio Inc?
The market capitalization of Climb Bio Inc is 616.21M.
Is Climb Bio Inc (CLYM) currently rated as Buy, Hold, or Sell?
According to analysts, Climb Bio Inc (CLYM) has an overall rating of STRONG BUY, with a price target of 20.93.
What is the Earnings Per Share (EPS TTM) of Climb Bio Inc (CLYM)?
The Earnings Per Share (EPS TTM) of Climb Bio Inc (CLYM) is -0.88.